Skip to main content
Top

Current Treatment Options in Oncology

Issue 1/2012

Content (10 Articles)

Endocrine Tumors (O Clark and A Dackiw, Section Editors)

Extent of Surgery for Papillary Thyroid Cancer: Preoperative Imaging and Role of Prophylactic and Therapeutic Neck Dissection

Robin M. Cisco, Wen T. Shen, Jessica E. Gosnell

Endocrine Tumors (O Clark and A Dackiw, Section Editors)

Parathyroid Carcinoma: Update and Guidelines for Management

Christina H. Wei, Avital Harari

Endocrine Tumors (O Clark and A Dackiw, Section Editors)

Neuroendocrine Pancreatic Tumors: Guidelines for Management and Update

William R. Burns, Barish H. Edil

Head and Neck Cancer (T Day, Section Editor)

Current Treatment Options for Metastatic Head and Neck Cancer

Katharine A. R. Price, Ezra E. Cohen

Head and Neck Cancer (T Day, Section Editor)

Well Differentiated Thyroid Carcinoma: Current Treatment

J. Kenneth Byrd, Robert J. Yawn, Christina S. T. Wilhoit, Nicoleta D. Sora, Linda Meyers, Jyotika Fernandes, Terry Day

Head and Neck Cancer (T Day, Section Editor)

Recurrent Salivary Gland Cancer

M. Boyd Gillespie, W. Greer Albergotti, David W. Eisele

Head and Neck Cancer (T Day, Section Editor)

mTOR Inhibitors and its Role in the Treatment of Head and Neck Squamous Cell Carcinoma

Shaun A. Nguyen, David Walker, M. Boyd Gillespie, J. Silvio Gutkind, Terry A. Day

Lymphomas (L Gordon, Section Editor)

Emerging Therapeutic Targets in Diffuse Large B-Cell Lymphoma

Murali Janakiram, Venu K. Thirukonda, Matthew Sullivan, Adam M. Petrich

Lymphomas (L Gordon, Section Editor)

Cutaneous T-Cell Lymphomas: A Review of New Discoveries and Treatments

Tara Bloom, Timothy M. Kuzel, Christiane Querfeld, Joan Guitart, Steven T. Rosen

Lymphomas (L Gordon, Section Editor)

Post Transplant Lymphoproliferative Disorders: Risk, Classification, and Therapeutic Recommendations

Deepa Jagadeesh, Bruce A. Woda, Jacqueline Draper, Andrew M. Evens

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine